Diabetes Mellitus and associated cardiovascular and renal risks have rapidly increased the morbidity and mortality rates globally. Therefore there is need for developing therapeutic approach that illustrate excellent glycemic control along with beneficial cardiorenal outcomes, that would ultimately improve the patient survival. Empagliflozin is one such glycemic control agent which has shown to go beyond glycemic control and demonstrate excellent cardiorenal outcomes . Boehringer Ingelheim and Docplexus invite you for an interactive LIVE webinar on 15 th March, 2017 at 3 pm with Dr. Vijay Panikar and Dr.
Brian Pinto . This webinar session details the Learnings from the Empa-Reg Outcome Trial in Improving Survival in Type 2 Diabetes Patients . Disclaimer: The views expressed are those of the respective doctors and do not necessarily reflect those of the publisher or sponsor. Please…
